Establishing a New Protocol for Early Mucositis and Peri-implantitis Treatment Using an Air-polishing Device (PERIFLOW)

Toulouse University Hospital

Status

Withdrawn

Conditions

Mucositis

Peri-Implantitis

Treatments

Device: Air-polishing device

Study type

Interventional

Funder types

Other

Identifiers

NCT03348111

RC31/15/7854

2016-A00754-47 (Other Identifier)

Details and patient eligibility

About

Considering the frequent occurence of peri-implantitis and mucositis, a multiple of treatment alternatives have been proposed including non-surgical and surgical procedures. However, it seems that the most effective treatment remains prevention of these diseases.

The aim of this study is to emphasize on mucositis and peri-implantitis prevention using an air abrasion device the Air-Flow Master Piezon® with erythritol and chlorhexidine powder in order to eliminate and / or disorganize the biofilm responsible for peri-implant mucosa inflammation.

Full description

Peri-implant infections (mucositis and peri-implantitis) depict an increasing focus in dental practice and implantology. mean prevalence of mucositis is of 43% and periimplantitis of 22%. Consequences for the implant without successful treatment range from local reversible inflammation (mucositis) to implant loss (periimplantitis). These lead to functional, social and esthetic prejudices for patients. The main factor for establishment of peri-implant infections is the formation and maturation of the bacterial biofilm. Peri-implantitis and mucositis treatment require the removal of the bacterial biofilm and the disinfection of the implant surface. Because of special surface conditions and structures, it is more difficult to remove bacterial biofilms from implant surfaces than teeth. the key to controlling the inflammation due to the bacterial biofilm is to prevent its installation and progression. The procedure tested in this study is an air abrasion device, the Air-Flow Master Piezon® with erythritol and chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally by disorganizing and eliminating the biofilm. Follow-up of the patients will be held every 2 months for 6 months by scoring the bleeding on probing, the plaque index and measuring clinical attachment level in order to compare it with the initial measure. At 6 month an X-ray will also enable to compare bone level and mineralization. This initial study will help establish a standardized protocol for peri-implant infection management.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

adult patients,
possessing one or more implants prosthetically engaged with local peri-implant mucosa inflammation assessed by bleeding on probing
affiliated with a social security scheme

Exclusion criteria

patients with implant mobility or implants associated with vestibular cellulitis
not available patients for the follow-up visits
patients with known allergy to erythritol and/or Chlorhexidine powder
patients with chronic bronchitis
patients with asthma
patients with endocarditis
patients with contagious disease
patients with immunodeficiency
patients under radiotherapy and/or chemotherapy and/or antibiotics
not mastery of plaque control on the part of the patient (after education)
subjects under legal protection
pregnant or breastfeeding women